Tobacco Control, Medicaid Coverage, and the Demand for Smoking Cessation Drugs

B-Tier
Journal: American Journal of Health Economics
Year: 2017
Volume: 3
Issue: 4
Pages: 528-549

Authors (5)

Michael R. Richards (not in RePEc) Joachim Marti (not in RePEc) Johanna Catherine Maclean (not in RePEc) Jason Fletcher (University of Wisconsin-Madiso...) Donald Kenkel (Cornell University)

Score contribution per author:

0.402 = (α=2.01 / 5 authors) × 1.0x B-tier

α: calibrated so average coauthorship-adjusted count equals average raw count

Abstract

To date, there has been limited research on what drives demand for smoking cessation products, especially pharmaceutical interventions. In this study, we use the near-universe of smoking cessation pharmaceutical prescriptions (1999–2012) to estimate the demand response to several anti-smoking policies (cigarette taxes, smoking bans, and Medicaid benefits). Our differences-in-differences estimates suggest an increase of 20 prescriptions per 10,000 persons following the introduction of Medicaid coverage, while taxes and bans demonstrate a less clear impact at the state level. Consumers appear sensitive to out-of-pocket cessation medication costs, which has relevance to recent Affordable Care Act insurance expansions and coverage regulations.

Technical Details

RePEc Handle
repec:ucp:amjhec:v:3:y:2017:i:4:p:528-549
Journal Field
Health
Author Count
5
Added to Database
2026-01-25